Anthem FY26 PAT Up 31% to ₹5,918 Mn

Anthem Biosciences reported FY26 consolidated revenue of ₹21,243 Mn with 15.2% YoY growth and PAT of ₹5,918 Mn with 31.1% YoY growth.
Q4FY26 revenue grew 26.4% YoY to ₹6,109 Mn with PAT surging 129.8% YoY to ₹1,898 Mn driven by strong CRDMO performance.
Company maintained net cash position of ₹13,743 Mn as of March 31, 2026 with EBITDA margins at 43.4% for FY26.
Management cited prudent cost management and focus on long-term value creation as key drivers for margin expansion.